Luzius H, Jans D A, Jans P, Fahrenholz F
Max-Planck-Institut für Biophysik, Frankfurt am Main, Federal Republic of Germany.
Exp Cell Res. 1991 Aug;195(2):478-84. doi: 10.1016/0014-4827(91)90399-f.
A novel mutant of the LLC-PK1 renal epithelial cell line, VPR1, was isolated after mutagenesis with N-methyl-N'-nitro-N-nitrosoguanidine and selection using a photoactivatable vasopressin analogue [1-(3-mercapto)propionic acid, 8-(N6-4-azidophenylamidino)lysine] vasopressin. The VPR1 mutant cell line possessed less than 5% parental V2 receptor binding for vasopressin but exhibited normal calcitonin receptor binding. In contrast to LLC-PK1 cells (wild type), VPR1 cells exhibited no response to vasopressin in terms of in vitro adenylate cyclase activation, in vivo cAMP production, or urokinase-type plasminogen activator induction. The responses of VPR1 cells to other agents, such as calcitonin, the adenylate cyclase activator forskolin, the GTP analogue guanosine 5'-[beta, gamma-imino] triphosphate, 8-bromo adenosine-3',5'-monophosphate were comparable to those of the parental cell line. Somatic cell hybrids were derived from the cell lines LLC-PK1 and VPR1 and analyzed for the dominance/recessiveness of the VPR1 mutant phenotype. Hybrids were found to possess normal vasopressin binding activity as well as functional responses to the hormone, indicating that the mutation affecting the V2 receptor in VPR1 cells is recessive. The VPR1 cell line may thus have application as a recipient for the expression of the V2 receptor gene using DNA-transfer.
用N-甲基-N'-硝基-N-亚硝基胍诱变并使用光活化加压素类似物[1-(3-巯基)丙酸,8-(N6-4-叠氮基苯甲脒基)赖氨酸]加压素进行筛选后,分离出了LLC-PK1肾上皮细胞系的一种新型突变体VPR1。VPR1突变细胞系对加压素的亲本V2受体结合能力不到5%,但降钙素受体结合能力正常。与LLC-PK1细胞(野生型)不同,VPR1细胞在体外腺苷酸环化酶激活、体内环磷酸腺苷(cAMP)产生或尿激酶型纤溶酶原激活剂诱导方面对加压素无反应。VPR1细胞对其他试剂,如降钙素、腺苷酸环化酶激活剂福斯可林、GTP类似物鸟苷5'-[β,γ-亚氨基]三磷酸、8-溴腺苷-3',5'-单磷酸的反应与亲本细胞系相当。体细胞杂种源自LLC-PK1和VPR1细胞系,并对VPR1突变表型的显性/隐性进行了分析。发现杂种具有正常的加压素结合活性以及对该激素的功能反应,表明影响VPR1细胞中V2受体的突变是隐性的。因此,VPR1细胞系可作为使用DNA转移表达V2受体基因的受体。